Vaccine. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar

[Giuseppe]

Vaccine. 2009 Feb 27. [Epub ahead of print]

Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens JG, Kino Y, Kistner O, Kompier R, Makizumi K, Medema J, Mimori S, Ryan D, Schwartz R, Smith JS, Sugawara K, Trusheim H, Tsai TF, Krause R. - National Institute for Biological Standards and Control, South Mimms, Potters Bar, Herts EN6 3QG, UK.

A meeting was held at NIBSC, UK in July 2007 to discuss the implications of progress in the use of cell culture systems for the manufacture of vaccines against influenza. Issues discussed included the effect of using eggs and different cell types in strain selection, development of seed viruses to be used in production and the nature of the reagents to be used in determining vaccine potency. Future studies to progress the field were reviewed.

PMID: 19366582 [PubMed - as supplied by publisher]
-
-----

 

[gsgs]

Re: Vaccine. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

so, that was 2007.

Meanwhile we have cell-based seasonal vaccine.
Apparantly it's more expensive than egg-vaccine.
(20%-50% ?)

but it bears the potential of faster availability and
possibility of scaling up in a pandemic